Physician profile
Constantine E Kosmas
NPI 1407855075
$14,299.65
in general payments reported to CMS, 2019-2025
18 companies · $63.48 in 2025
The $63.48 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $12K · 2021: $1,049 · 2022: $82.61 · 2025: $63.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $11,504.13 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $665.42 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $588.65 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $462.52 | 2019-2022 | |
| Amgen INC. | $328.89 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $222.04 | 2020-2021 | |
| Esperion Therapeutics, INC. | $80.16 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $77.13 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $72.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.42 | 2021-2022 | |
| Pfizer INC. | $63.48 | 2025 | |
| Althera Pharmaceuticals LLC | $60.04 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $25.12 | 2019 | |
| Braemar Manufacturing, LLC | $19.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.23 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.18 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.01 | 2020 | |
| Philips North America LLC | $13.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantine Kosmas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.